23.03.2016 • News

Freeport Chosen for MEGlobal’s US Plant

MEGlobal, a wholly-owned subsidiary of Kuwait’s Equate Petrochemical, has announced it will build a world-scale MEG plant at Dow Chemical’s Oyster Creek site in Freeport, Texas, USA.

The plant is planned to go on stream in mid-2019. Capacity details were not disclosed.

Dow’s CEO Andrew Liveris stated last year that MEGlobal would build somewhere on the US Gulf, depending on the incentives offered. Texas was chosen following the approval of tax agreements which Dow said would help maintain a favorable climate in the state for future business approval and development by both itself and MEGlobal.

The facility will be MEGlobal’s first production plant in the US and will benefit from a long-term ethylene supply agreement with Dow, which is currently building a new cracker at Freeport. Construction is more than 40% complete, and the ethylene plant is said to be on track for start-up in the second quarter of 2017.

“Establishing MEG production in the US Gulf Coast is an important investment for us as it greatly enhances our global footprint and is directly aligned to our growth strategy to maximize value as a leading ethylene glycol producer and supplier,” said Mohammad Husain, Equate’s president and CEO. He added that the supply agreement with Dow also provides the plant with a unique competitive position.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read